Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tepotinib plus cetuximab in platinum‑resistant head and neck squamous cell carcinoma after immunotherapy
2022-002841-17Phase 2Active
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Nov 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tepotinib and cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by ASST Spedali Civili di Brescia. Primary endpoint: Objective response rate. Started Nov 2022; status: active.
02
Drugs
tepotinibcetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2022-002841-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002841-17.